Please try another search
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. The company develops a pipeline of POZ enabled drugs for central nervous system indications, such as Parkinson’s disease, epilepsy, and pain. Its lead product candidate includes SER 252, a POZ conjugate that is in preclinical development, for the treatment of Parkinson’s disease. In addition, the company develops, SER 227, indicated for relief of long-acting pain; SER 228, which is in preclinical development, for the treatment of epilepsy; and poly (2-oxazoline), a POZ drug delivery technology. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
Name | Age | Since | Title |
---|---|---|---|
J. Milton Harris | 83 | 2024 | Director |
Steven A. Ledger | 65 | 2024 | Interim CEO & Director |
Balkrishan Gill | 59 | 2024 | Executive Chairman |
Remy Gross | 54 | 2024 | Director |
Richard Marshall | 57 | 2024 | Director |
Charles Warren Olanow | - | - | Member of Scientific Advisory Board |
Steven Michael Mintz | 58 | 2024 | Director |
Gregory H. Bailey | 68 | 2024 | Director |
William K. Schmidt | 73 | - | Member of Scientific Advisory Board |
Gaurav Sahay | - | - | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review